Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
MWN-AI** Summary
Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a key player in developing adult stem cell therapies for neurodegenerative diseases, recently announced a strategic private placement of $1 million. This financing, aimed at advancing its potent NurOwn® platform, reflects the company’s operational momentum and the intrinsic value of its technologies.
The financing was structured at a premium, with the common stock priced at $0.60 per share—significantly above the $0.54 closing price from February 9, 2026. An additional 120% warrant coverage for five years is included, with a strike price of $1.00 per share, indicating strong long-term confidence from institutional investors. The financing will be executed in two tranches, the first of which, amounting to $500,000, has already been received, with the second tranche expected within 30 days.
CEO Chaim Lebovits emphasized this financing as a vote of confidence in Brainstorm's future, considering the promising pathway of NurOwn® as a therapy for amyotrophic lateral sclerosis (ALS). The company is actively finalizing designs for its Phase 3b trial under a Special Protocol Assessment and is engaged with regulatory bodies regarding its Citizens Petition for Accelerated Approval.
The proceeds from this financing will support ongoing regulatory initiatives, cover prepayments for the upcoming clinical trials, and assist in general corporate purposes. Brainstorm continues to strengthen its intellectual property and explore further applications of its stem cell technology, highlighting its commitment to innovation and impacting the ALS patient community positively.
Overall, this financing positions Brainstorm for strategic growth as it advances its clinical programs and regulatory efforts in the dynamic field of regenerative medicine.
MWN-AI** Analysis
Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI) recently announced a $1 million strategic financing at a premium to its market price, signifying strong institutional confidence in its capabilities and prospects, especially regarding its lead product, NurOwn®. The common stock was priced at $0.60 per share, representing a notable premium over its closing price of $0.54 on February 9, 2026.
Investors should view this development as a positive signal amid a pivotal phase for the company. The financing structure includes a warrant coverage of 120% over five years with an exercise price of $1.00 per share, which suggests robust expectations from institutional backers about Brainstorm’s future valuation. This could indicate a potential upward trend for the stock, especially as the company gears up for its Phase 3b trial under a Special Protocol Assessment (SPA) from the FDA.
The funds from this financing will be allocated to support ongoing regulatory initiatives and further preparations for the Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS), bolstering the company’s clinical path. Given that NurOwn® has received Orphan Drug designation from the FDA and the EMA, it is positioned favorably in the medical community, which enhances its marketability.
While the price increase might suggest bullish sentiment, investors should remain cognizant of the inherent risks associated with biotech stocks, particularly around regulatory approvals and clinical outcomes. Forward-looking statements from management highlight ongoing uncertainties in achieving desired outcomes.
In conclusion, Brainstorm Cell Therapeutics presents an intriguing opportunity for investors, particularly those interested in the biotech sector focusing on neurodegenerative diseases. Given the premium financing and its strategic importance for further clinical advancement, BCLI could represent a compelling investment, particularly for risk-tolerant investors with a long-term perspective. However, vigilance around regulatory developments and trial results remains essential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NEW YORK, Feb. 20, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a definitive agreement for a strategic private placement of $1 million.
The financing was structured to reflect the company's current operational momentum and the underlying value of its NurOwn® platform.
Key Terms of the Financing:
- Premium Pricing: The common stock was priced at $0.60 per share, representing a significant premium to the $0.54 closing price on Monday, February 9, 2026, the date the transaction was finalized.
- Warrant Structure: The investment includes 120% warrant coverage for five years with an exercise price of $1.00 per share. This strike price represents a nearly 100% premium to the recent market close, signaling a strong long-term valuation target from institutional partners.
- Staged Funding: The financing is being completed in two tranches, with the first payment of $500,000 already received and the final payment of $500,000 scheduled for receipt within 30 days.
- Registration Rights: The Company must file a registration statement registering the resale of the common stock and warrants within 45 days.
The financing follows a period of intense strategic activity for BrainStorm, as the company finalizes its Phase 3b trial design under a Special Protocol Assessment (SPA) and engages in high-level discussions regarding the pending Citizens Petition for Accelerated Approval.
"Securing this financing at a premium to the current market is a powerful vote of confidence in the trajectory of Brainstorm," said Chaim Lebovits, President and CEO of Brainstorm. "Our partners have recognized the immense potential of our regulatory and clinical path to advance NurOwn as an innovative treatment for ALS. The $1.00 warrant strike price, in particular, serves as a clear indicator of where we believe this company is headed as we make final preparations for our planned Phase 3b trial and continue our high-level engagement with regulatory authorities. We remain committed to the ALS patient community, the science and our targeted goal of commercializing NurOwn."
The company filed a Form 8-K regarding this transaction with the Securities and Exchange Commission on Friday, February 13, 2026.
Proceeds from the financing will be used to support ongoing regulatory initiatives, prepayments for the upcoming Phase 3b trial of NurOwn® in ALS, and general corporate purposes.
The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" - a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Investors:
Michael Wood
Phone: +1 646-597-6983
mwood@lifesciadvisors.com
Media:
Uri Yablonka,
Chief Business Officer
Phone: +1 917-284-2911
uri@brainstorm-cell.com
Photo:https://mma.prnewswire.com/media/1166536/5459259/BrainStorm_Logo.jpg
SOURCE BrainStorm Cell Therapeutics Inc.
FAQ**
How does the $1 million strategic financing at a premium to market reflect the confidence in Brainstorm Cell Therapeutics Inc. BCLI's NurOwn® platform and its potential in treating neurodegenerative diseases like ALS?
What specific regulatory initiatives and preparations for the Phase 3b trial will the proceeds from the $1 million financing for Brainstorm Cell Therapeutics Inc. BCLI support?
Considering the warrant structure with a $1.00 exercise price, how does Brainstorm Cell Therapeutics Inc. BCLI foresee its long-term valuation in relation to the recent market close?
What are the potential impacts of the pending Citizens Petition for Accelerated Approval on Brainstorm Cell Therapeutics Inc. BCLI's timeline for bringing NurOwn® to market?
**MWN-AI FAQ is based on asking OpenAI questions about Brainstorm Cell Therapeutics Inc. (OTC: BCLI).
NASDAQ: BCLI
BCLI Trading
1.43% G/L:
$0.923 Last:
26,319 Volume:
$0.91 Open:
